Výsledky vyhledávání - "Jamie N. Holloway"

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

Autor: Gwynn Ison, Raymond U. Osarogiagbon, Tithi Biswas, Madison M. Wempe, Sol Atienza, Diana Merino Vega, James L. Wade, Peter De Porre, Jamie N. Holloway, Richard L. Schilsky, Suparna Wedam, Edward S. Kim, Lola Fashoyin-Aje, David S. Hong

Publikováno v: Clinical Cancer Research. 27:2408-2415

Purpose: Restrictive eligibility criteria induce differences between clinical trial and “real-world” treatment populations. Restrictions based on prior therapies are common; minimizing them when appropriate may increase patient participation in c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::19eb7611be7662a5325d5cc18363eaf3
https://doi.org/10.1158/1078-0432.ccr-20-3854

Zobrazit plný text záznamu

Promoting Scientist–Advocate Collaborations in Cancer Research: Why and How

Autor: Deborah Charles Chisholm, Jeannine M. Salamone, Susan Winarsky, Jamie N. Holloway, Naomi Greenwood, Ayesha N. Shajahan-Haq, Julia Maues, Erin Price, Shelley B. Brundage, Kirsten B. Baker, Roberta Carlin, Margery London, Nora E. Carbine, Wanda Lucas, Rosa Goyes, Sherri M. Stahl

Publikováno v: Cancer Research. 78:5723-5728

Advocates bring unique and important viewpoints to the cancer research process, ensuring that scientific and medical advances are patient-centered and relevant. In this article, we discuss the benefits of engaging advocates in cancer research and und

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c585fd576750fed596bd5f801dbf8c29
https://doi.org/10.1158/0008-5472.can-18-1600

Zobrazit plný text záznamu

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Autor: Michael J. Hassett, Antonio C. Wolff, Mark R. Somerfield, Neelima Denduluri, Tari A. King, Andrea Eisen, Ann H. Partridge, Jamie N. Holloway, Gary H. Lyman, Arti Hurria, Stephanie L. Graff, Sharon H. Giordano, Melinda L. Telli, Mariana Chavez-MacGregor, Maureen E. Trudeau

Publikováno v: Journal of Clinical Oncology. 36:2433-2443

Purpose To update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer. Methods An

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d1a37786d7a1b8750d4d2e57efa7cc
https://doi.org/10.1200/jco.2018.78.8604

Zobrazit plný text záznamu

ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization

Autor: Karen L. Chen, Sarah Li, Yiru Chen Zhao, Alexander E. Lipka, Partha S. Ray, Eylem Kulkoyluoglu, Rebecca L. Smith, Tania Ray, Jamie N. Holloway, Kadriye Hieronymi, Yosef Landesman, Zeynep Madak-Erdogan, Kinga Wrobel

Publikováno v: Molecular Endocrinology

Most breast cancer deaths occur in women with recurrent, estrogen receptor (ER)-α(+), metastatic tumors. There is a critical need for therapeutic approaches that include novel, targetable mechanism-based strategies by which ERα (+) tumors can be re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2019b3bba0ce249cf020362aa506a8
https://doi.org/10.1210/me.2016-1101

Zobrazit plný text záznamu

Abstract P5-10-01: Patient advocates as partners in breast cancer research at Georgetown University Lombardi Comprehensive Cancer Center

Autor: Ayesha N. Shajahan-Haq, N Carbine, S Brundage, Claudine Isaacs, W Lucas, M London, S Winarsky, R Goyes, E Ernst, Robert Clarke, E Price, J Salamone, D Charles Chisholm, S Stahl, N Greenwood, Jamie N. Holloway, K-G Leventhal

Publikováno v: Cancer Research. 76:P5-10

The integration of patient advocate input into biomedical research grant proposals is a relatively new phenomenon and represents a paradigm shift for basic, translational and clinical researchers seeking funding for their proposed studies. In 2011, t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e333859ee740926533c44a260343d21
https://doi.org/10.1158/1538-7445.sabcs15-p5-10-01

Zobrazit plný text záznamu

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline

Autor: Gary H. Lyman, Melinda L. Telli, Arti Hurria, Jamie N. Holloway, Neelima Denduluri, Maureen E. Trudeau, Tari A. King, Andrea Eisen, Mark R. Somerfield, Antonio C. Wolff, Ann H. Partridge

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(20)

Purpose A Cancer Care Ontario (CCO) guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including adjuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)–positive breast cancers was ide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::834dbf4a3a3ba3f3e877a1c8229b5ce7
https://pubmed.ncbi.nlm.nih.gov/28355523

Zobrazit plný text záznamu

A Cytoplasmic Substrate of Mitogen-Activated Protein Kinase Is Responsible for Estrogen Receptor-α Down-Regulation in Breast Cancer Cells: The Role of Nuclear Factor-κB

Autor: Shalini Murthy, Dorraya El-Ashry, Jamie N. Holloway

Publikováno v: Molecular Endocrinology. 18:1396-1410

Estrogen receptor alpha (ERalpha) negative breast tumors often present with enhanced expression and/or activation of growth factor receptors, resulting in increased growth factor signaling and hyperactivation of MAPK (ERK1 and ERK2). We have pre-viou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::672a42934b6ddf583bcbf04347bb0d53
https://doi.org/10.1210/me.2004-0048

Zobrazit plný text záznamu

Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells

Autor: David L. Miller, Lori A. Lorant, Jamie N. Holloway, Francis G. Kern, Annabell S. Oh, Dorraya El-Ashry

Publikováno v: Molecular Endocrinology. 15:1344-1359

ERalpha-negative breast tumors tend to overexpress growth factor receptors such as epidermal growth factor receptor or c-erbB-2. Raf-1 is a key intermediate in the signal transduction pathways of these receptors. High levels of constitutive Raf kinas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043074cecbe2ee485ed557eb9e6fb5c2
https://doi.org/10.1210/mend.15.8.0678

Zobrazit plný text záznamu

Abstract 1812: Targeting nuclear transport pathways to overcome endocrine resistance and recurrence

Autor: Rebecca L. Smith, Zeynep Madak Erdogan, Kadriye Hieronymi, Eylem Kulkoyluoglu, Kinga Wrobel, Alexander E. Lipka, Partha S. Ray, Yiru Chen Zhao, Yosef Landesman, Jamie N. Holloway, Karen L. Chen, Tania Ray

Publikováno v: Cancer Research. 76:1812-1812

Currently, around 75% of patients with breast tumors test positive for estrogen receptor alpha (ERa) and are treated with endocrine therapies, such as tamoxifen. One-third of the breast tumors eventually become refractory, reducing the survival rate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aea3aaa42ad8f8d8ba2fd76e2128024a
https://doi.org/10.1158/1538-7445.am2016-1812

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání